Andrea Espejo-Freire

Dr. Andrea Espejo-Freire

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in American Journal of Clinical Pathology
Verified
Journal Article
Closed access
AEAndrea Espejo-Freire
Andrea Espejo-Freire
YAYamac Akgun
Yamac Akgun
AMAbdulaziz F Al Mana
Abdulaziz F Al Mana
YTYouley Tjendra
Youley Tjendra
NMNicolas C Millan
Nicolas C Millan
Carolyn CrayCarolyn Cray
Carolyn Cray
Objectives: To examine and summarize the current literature on serologic methods for the detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods: A literature review was performed using searches in databases including PubMed, medRxiv, and bioRxiv. Thirty-two peer-reviewed papers and 23 preprints were examined. Results: The studies included lateral flow immunoassay, enzyme-linked immunosorbent assay, chemiluminescence immunoassay, and neutralizing antibody assays. The use of all major SARS-CoV-2 antigens was demonstrated to have diagnostic value. Assays measuring total antibody reactivity had the highest sensitivity. In addition, all the methods provided opportunities to characterize the humoral immune response by isotype. The combined use of IgM and IgG detection resulted in a higher sensitivity than that observed when detecting either isotype alone. Although IgA was rarely studied, it was also demonstrated to be a sensitive marker of infection, and levels correlated with disease severity and neutralizing activity. Conclusions: The use of serologic testing, in conjunction with reverse transcription polymerase chain reaction testing, was demonstrated to significantly increase the sensitivity of detection of patients infected with SARS-CoV-2. There was conflicting evidence regarding whether antibody titers correlated with clinical severity. However, preliminary investigations indicated some immunoassays may be a surrogate for the prediction of neutralizing antibody titers and the selection of recovered patients for convalescent serum donation.

26 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AEAndrea Espejo-Freire
Andrea Espejo-Freire
AEAndrew Elliott
Andrew Elliott
ARAndrew Rosenberg
Andrew Rosenberg
PCPhilippos Cot
Philippos Cot
PBPriscila Barreto-Coelho
Priscila Barreto-Coelho
Jonathan TrentJonathan Trent
Jonathan Trent
We performed a retrospective analysis of angiosarcoma (AS) genomic biomarkers and their associations with the site of origin in a cohort of 143 cases. Primary sites were head and neck (31%), breast (22%), extremity (11%), viscera (20%), skin at other locations (8%), and unknown (9%). All cases had Next Generation Sequencing (NGS) data with a 592 gene panel, and 53 cases had Whole Exome Sequencing (WES) data, which we used to study the microenvironment phenotype. The immunotherapy (IO) response biomarkers Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), and PD-L1 status were the most frequently encountered alteration, present in 36.4% of the cohort and 65% of head and neck AS (H/N-AS) (p < 0.0001). In H/N-AS, TMB-High was seen in 63.4% of cases (p < 0.0001) and PDL-1 positivity in 33% of cases. The most common genetic alterations were TP53 (29%), MYC amplification (23%), ARID1A (17%), POT1 (16%), and ATRX (13%). H/N-AS cases had predominantly mutations in TP53 (50.0%, p = 0.0004), POT1 (40.5%, p < 0.0001), and ARID1A (33.3%, p = 0.5875). In breast AS, leading alterations were MYC amplification (63.3%, p < 0.0001), HRAS (16.1%, p = 0.0377), and PIK3CA (16.1%, p = 0.2352). At other sites, conclusions are difficult to generate due to the small number of cases. A microenvironment with a high immune signature, previously associated with IO response, was evenly distributed in 13% of the cases at different primary sites. Our findings can facilitate the design and optimization of therapeutic strategies for AS.

31 March 2020 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
YJYuqi Jing
Yuqi Jing
VCValery Chavez
Valery Chavez
NKNatasha Khatwani
Natasha Khatwani
YBYuguang Ban
Yuguang Ban
AEAndrea Espejo-Freire
Andrea Espejo-Freire
JMJaime R. Merchan
Jaime R. Merchan

2 July 2021 in Preprints.org
Verified
Preprint
Open access
AEAndrea Espejo-Freire
Andrea Espejo-Freire
AEAndrew Elliot
Andrew Elliot
ARAndrew Rosenberg
Andrew Rosenberg
PCPhilippos Apolinario Costa
Philippos Apolinario Costa
PCPriscila Barreto Coelho
Priscila Barreto Coelho
Jonathan TrentJonathan Trent
Jonathan Trent
We performed a comprehensive analysis of angiosarcoma (AS) genomic biomarkers and their associations with the site of origin. We aimed to describe the genomic landscape of AS in a cohort of 143 cases of AS profiled by Caris Life Sciences. Data of Next Generation Sequencing (NGS) with a 592 gene panel was available for the entire cohort. Fifty-three cases had data of Whole Exome Sequencing (WES) which we used to study the microenvironment phenotype. Immuno-therapy (IO) response biomarkers: Tumor Mutation Burden (TMB), Microsatellite Instability (MSI) and PD-L1 status were included. IO-response markers were present in 36.4% of the cohort and in 65% of head and neck AS (H/N-AS) (p<0.0001). H/N-AS cases had predominantly muta-tions in TP53 (50.0%, p=0.0004), POT1 (40.5%, p<0.0001) and ARID1A (33.3%, p=0.5875). In breast AS, leading alterations were MYC amplification (63.3%, p<0.0001), HRAS (16.1%, p=0.0377), and PI3KCA (16.1%, p=0.2352). A microenvironment with a high immune signature, associated with better response to IO, was present in 13% of the cases. This signature was evenly distributed among different primary sites. We found that the molecular biology for AS varies significantly according to the primary site. Our findings can facilitate the design and optimiza-tion of therapeutic strategies for AS to overcome resistance to IO and targeted therapies.

1 January 2018 in Rare Tumors
Verified
Journal Article
Open access
PDF file
AEAndrea Espejo-Freire
Andrea Espejo-Freire
JRJeremy L Ramdial
Jeremy L Ramdial
BWBreelyn A Wilky
Breelyn A Wilky
DKDarcy A Kerr
Darcy A Kerr
JTJonathan C Trent
Jonathan C Trent
In patients with sarcoma, concomitant malignancy is found in 1.2% -2.5% of cases. Previous studies have demonstrated conflicting results in terms of positive or negative effects on cancer prognosis with comorbid sarcoidosis. Additionally, there are no data determining whether an association between sarcoidosis and sarcomas exists. Finding an association between the two entities could prevent inadvertent upstaging of a primary sarcoma based on pulmonary nodularity mistaken for metastatic disease. Here, we will describe eight sarcoma patients with concomitant occurrence of sarcoidosis identified since 2007. Eight patients with diagnosis of both sarcoma and sarcoidosis were identified over the period of 2007 -2016 at a single sarcoma center. Clinical and historical data including presentation, histology, treatment, and outcome was tabulated for analysis. The standardized incidence ratio was calculated for the state of Florida and our hospital catchment area. We compared the observed incidence to the expected incidence if the two entities were to be unrelated. Sarcoma subtype was gastrointestinal stromal tumor in five patients, the remaining three cases were unclassified spindled and epithelioid cell sarcoma, uterine leiomyosarcoma, and myxofibrosarcoma. Sarcoidosis was diagnosed before sarcoma in three patients, after sarcoma in four patients, and at the same time of sarcoma diagnosis in one patient. From our series, three patients have shown no progression of sarcoma, two are alive with sarcoma, two died due to progression of sarcoma, and one was lost to follow up. Statistical analyses showed a standardized incidence ratio of 305 (95% confidence interval: 131 -556) for the state of Florida and standardized incidence ratio of 950 (95% CI: 407 -1727) for our catchment area. This case series points to a statistically robust, nonrandom association between sarcoma and sarcoidosis that has not been previously described. Presumed metastatic sarcoma should be considered for biopsy particularly with demographic characteristics or imaging features suggestive of sarcoidosis.

1 May 2022 in JCO Precision Oncology
Verified
Journal Article
Closed access
PBPriscila Barreto-Coelho
Priscila Barreto-Coelho
ARAndrew Rosenberg
Andrew Rosenberg
TSTy Subhawong
Ty Subhawong
PCPhilippos Cot
Philippos Cot
AEAndrea Espejo-Freire
Andrea Espejo-Freire
GDGina Z. D'AMato
Gina Z. D'AMato
Targeted therapy for PPP1R21-ALK rearrangement generates a radical response in a case of severe IV leiomyomatosis. The first successful case of ALK-targeted therapy in a rearrangement is not previo...